Advertisement

Braintree-based Haemonetics (NYSE: HAE), a blood management company, announced that it has completed the previously-announced acquisition of the blood collection, filtration and processing product lines of Pall Corp. for $550 million, and also reported its first quarter 2013 results.

Advertisement
Advertisement